| scholarly article | Q13442814 |
| P2093 | author name string | Sean P Curtis | |
| Alise S Reicin | |||
| Chester Fisher | |||
| Barry Bockow | |||
| Amy T Ko | |||
| Amy Compton | |||
| Joseph Olaleye | |||
| P2860 | cites work | Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 |
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Renal effects of COX-2-selective inhibitors | Q34199155 | ||
| Pharmacological therapy of osteoarthritis | Q34376732 | ||
| Renal toxicity of the nonsteroidal anti-inflammatory drugs | Q34731188 | ||
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials | Q35680546 | ||
| Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. | Q44123837 | ||
| Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib | Q44282395 | ||
| Development and progression of osteoarthritis | Q71699458 | ||
| Bone marrow: a fountain of vascular youth? | Q73718568 | ||
| Etoricoxib | Q80471891 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| P304 | page(s) | 58 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | BMC Musculoskeletal Disorders | Q15751716 |
| P1476 | title | Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. | |
| P478 | volume | 6 |
| Q39906208 | Anticytokine therapy for osteoarthritis: evidence to date |
| Q90695739 | Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis |
| Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
| Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
| Q36861909 | Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments |
| Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
| Q35166773 | Etoricoxib for arthritis and pain management |
| Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
| Q48269682 | Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis |
| Q37773271 | Joint injury and osteoarthritis: soluble mediators in the course and treatment of cartilage pathology |
| Q38412511 | Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study |
| Q40976343 | Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal |
| Q53602109 | Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. |
Search more.